Literature DB >> 8421281

Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds.

R C Wade1, P J Goodford.   

Abstract

The specificity of interactions between biological macromolecules and their ligands may be partially attributed to the directional properties of hydrogen bonds. We have now extended the GRID method (Goodford, P. J. J. Med. Chem. 1985, 28, 849. Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.; Wade, R. C. J. Med. Chem. 1989, 32, 1083), of determining energetically favorable ligand binding sites on molecules of known structure, in order to improve the treatment of groups which can make multiple hydrogen bonds. In this method, the interaction energy between a probe (a small chemical group that may be part of a larger ligand) and a target molecule is calculated using an energy function which includes a hydrogen bond term which is dependent on the length of the hydrogen bond, its orientation at the hydrogen-bonding atoms, and their chemical character. The methods described in the preceding paper (Wade, R. C.; Clark, K. J.; Goodford, P. J. J. Med. Chem., preceding paper in this issue) for probes capable of making two hydrogen bonds are here extended to the following probes which have the ability to make more than two hydrogen bonds: ammonium-NH3+, amine-NH2, sp3-hybridized hydroxyl, and water. Use of the improved GRID procedure is demonstrated by the determination of the conformation of an amino acid side chain at the subunit interface in hemoglobin and of the location of water binding sites in human lysozyme.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8421281     DOI: 10.1021/jm00053a019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  31 in total

1.  A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors.

Authors:  A Poso; J Gynther; R Juvonen
Journal:  J Comput Aided Mol Des       Date:  2001-03       Impact factor: 3.686

2.  Computer based screening of compound databases: 1. Preselection of benzamidine-based thrombin inhibitors.

Authors:  T Fox; E E Haaksma
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

3.  A comparative docking study and the design of potentially selective MMP inhibitors.

Authors:  S Hanessian; N Moitessier; E Therrien
Journal:  J Comput Aided Mol Des       Date:  2001-10       Impact factor: 3.686

4.  Functional group placement in protein binding sites: a comparison of GRID and MCSS.

Authors:  R Bitetti-Putzer; D Joseph-McCarthy; J M Hogle; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2001-10       Impact factor: 3.686

5.  A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking.

Authors:  Stefano Forli; Arthur J Olson
Journal:  J Med Chem       Date:  2012-01-13       Impact factor: 7.446

6.  3D hydrogen bond thermodynamics (HYBOT) potentials in molecular modelling.

Authors:  Oleg A Raevsky; Vladlen S Skvortsov
Journal:  J Comput Aided Mol Des       Date:  2002-01       Impact factor: 3.686

7.  A Bayesian molecular interaction library.

Authors:  Ville-Veikko Rantanen; Mats Gyllenberg; Timo Koski; Mark S Johnson
Journal:  J Comput Aided Mol Des       Date:  2003-07       Impact factor: 3.686

8.  Gaussian mapping of chemical fragments in ligand binding sites.

Authors:  Kun Wang; Marta Murcia; Pere Constans; Carlos Pérez; Angel R Ortiz
Journal:  J Comput Aided Mol Des       Date:  2004-02       Impact factor: 3.686

9.  Dynamic water networks in cytochrome C oxidase from Paracoccus denitrificans investigated by molecular dynamics simulations.

Authors:  Elena Olkhova; Michael C Hutter; Markus A Lill; Volkhard Helms; Hartmut Michel
Journal:  Biophys J       Date:  2004-04       Impact factor: 4.033

10.  Molecular interaction fields (MIFs) to predict lipophilicity and ADME profile of antitumor Pt(II) complexes.

Authors:  Giulia Caron; Mauro Ravera; Giuseppe Ermondi
Journal:  Pharm Res       Date:  2010-11-17       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.